公开(公告)号：US07317025B2

公开(公告)日：2008-01-08

申请号：US10949055

申请日：2004-09-24

Applicant: Nicholas I. Carruthers ,  Wenying Chai ,  Scott L. Dax ,  Jill A. Jablonowski ,  Xiaobing Li ,  Timothy W. Lovenberg ,  William V. Murray ,  Dale A. Rudolph ,  Mark Seierstad ,  Mark A. Youngman

Inventor： Nicholas I. Carruthers ,  Wenying Chai ,  Scott L. Dax ,  Jill A. Jablonowski ,  Xiaobing Li ,  Timothy W. Lovenberg ,  William V. Murray ,  Dale A. Rudolph ,  Mark Seierstad ,  Mark A. Youngman

IPC: A61K31/445 ,  A61K31/405 ,  C07D209/00 ,  C07D209/02 ,  C07D209/04 ,  C07D211/00

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D409/14

Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

Abstract translation: 本发明提供了用于治疗或预防：抗焦虑障碍或抑郁症的新型非肽性NPY Y2受体抑制剂; 受伤的哺乳动物神经组织; 通过施用神经营养因子治疗反应的病症; 神经系统疾病; 骨质疏松 物质相关疾病; 肥胖; 或肥胖相关疾病。 本发明的化合物还可用于调节内分泌功能，特别是由垂体和下丘脑腺体控制的内分泌功能，因此可用于治疗或预防排卵和不育症。

公开(公告)号：US20070100141A1

公开(公告)日：2007-05-03

申请号：US11553556

申请日：2006-10-27

Applicant: Pascal Bonaventure ,  Nicholas Carruthers ,  Wenying Chai ,  Curt Dvorak ,  Jill Jablonowski ,  Dale Rudolph ,  Mark Seierstad ,  Chandravadan Shah ,  Devin Swanson ,  Victoria Wong

Inventor： Pascal Bonaventure ,  Nicholas Carruthers ,  Wenying Chai ,  Curt Dvorak ,  Jill Jablonowski ,  Dale Rudolph ,  Mark Seierstad ,  Chandravadan Shah ,  Devin Swanson ,  Victoria Wong

IPC: C07D413/02 ,  C07D403/02 ,  C07D401/02

CPC classification number: C07D295/15 ,  C07D205/04 ,  C07D207/06 ,  C07D207/08 ,  C07D207/10 ,  C07D207/27 ,  C07D207/34 ,  C07D211/14 ,  C07D211/16 ,  C07D211/22 ,  C07D211/34 ,  C07D211/38 ,  C07D211/58 ,  C07D211/70 ,  C07D213/55 ,  C07D213/56 ,  C07D213/74 ,  C07D213/81 ,  C07D213/82 ,  C07D231/14 ,  C07D237/20 ,  C07D239/28 ,  C07D239/48 ,  C07D241/04 ,  C07D261/08 ,  C07D261/14 ,  C07D285/01 ,  C07D295/135 ,  C07D295/155 ,  C07D295/185 ,  C07D307/24 ,  C07D307/52 ,  C07D307/68 ,  C07D333/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/08

Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

Abstract translation: 本发明提供了用于治疗或预防：抗焦虑障碍或抑郁症的新型非肽性NPY Y2受体抑制剂; 受伤的哺乳动物神经组织; 通过施用神经营养因子对治疗有反应的病症; 神经系统疾病; 骨质疏松 物质相关疾病; 睡眠/觉醒障碍 心血管疾病; 肥胖; 或肥胖相关疾病。 本发明的化合物还可用于调节内分泌功能，特别是由垂体和下丘脑腺体控制的内分泌功能，因此可用于治疗或预防未排卵和不育症。

公开(公告)号：US07541359B2

公开(公告)日：2009-06-02

申请号：US11478128

申请日：2006-06-28

Applicant: Richard Apodaca ,  J. Guy Breitenbucher ,  Kanaka Pattabiraman ,  Mark Seierstad ,  Wei Xiao

Inventor： Richard Apodaca ,  J. Guy Breitenbucher ,  Kanaka Pattabiraman ,  Mark Seierstad ,  Wei Xiao

IPC: A61K31/496 ,  A61K31/505 ,  A61K31/5377 ,  C07D285/135 ,  C07D417/04 ,  C07D417/12

CPC classification number: C07D285/08 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

Abstract: Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Abstract translation: 描述了如说明书中定义的某些式（I）的N-杂芳基哌嗪基脲化合物，其可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。

公开(公告)号：US20070004741A1

公开(公告)日：2007-01-04

申请号：US11478128

申请日：2006-06-28

Applicant: Richard Apodaca ,  J. Breitenbucher ,  Kanaka Pattabiraman ,  Mark Seierstad ,  Wei Xiao

Inventor： Richard Apodaca ,  J. Breitenbucher ,  Kanaka Pattabiraman ,  Mark Seierstad ,  Wei Xiao

IPC: A61K31/506 ,  A61K31/497 ,  A61K31/496 ,  C07D417/14 ,  C07D417/04

CPC classification number: C07D285/08 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

Abstract: Certain N-heteroarylpiperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Abstract translation: 描述了某些N-杂芳基哌嗪基脲化合物，其可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。

公开(公告)号：US20060173184A1

公开(公告)日：2006-08-03

申请号：US11321710

申请日：2005-12-29

Applicant: Richard Apodaca ,  J. Breitenbucher ,  Kanaka Pattabiraman ,  Mark Seierstad ,  Wei Xiao

Inventor： Richard Apodaca ,  J. Breitenbucher ,  Kanaka Pattabiraman ,  Mark Seierstad ,  Wei Xiao

IPC: C07D403/02

CPC classification number: C07D295/195 ,  C07D207/335 ,  C07D209/08 ,  C07D209/14 ,  C07D209/82 ,  C07D211/16 ,  C07D213/38 ,  C07D213/56 ,  C07D213/61 ,  C07D213/75 ,  C07D215/12 ,  C07D215/18 ,  C07D239/42 ,  C07D241/42 ,  C07D295/20 ,  C07D295/215 ,  C07D307/79 ,  C07D307/81 ,  C07D317/46 ,  C07D317/58 ,  C07D319/16 ,  C07D319/18 ,  C07D333/58 ,  C07D333/60 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

Abstract: Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).